Lipid-lowering therapies in development

Bibliography

• BUCHER HC, GRIFFITH LE, GUYATT GH: Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler. Thromb. Vase. Biol. (1999) 19:187–195.
   PubMed Web of Science ®Google Scholar
• •General review of benefits of lipid-lowering therapies.
   Google Scholar
• SACKS FM: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. Cardiol. (2002) 90:139–143.
   PubMed Web of Science ®Google Scholar
• CHAPMAN MJ, ASSMAN G, SHEPHERD J, SIRTORI C, on behalf of THE EUROPEAN CONSENSUS PANEL ON HDL-C: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr. Med. Res. Opin. (2004) 20:1253–1268.
   PubMed Web of Science ®Google Scholar
• ••Guideline on HDL-C targets to beachieved in clinical practice.
   Google Scholar
• WIERZBICKI AS, POSTON R, FERRO A: The lipid and non-lipid effects of statins. PharmacolTher. (2003) 99:95–112.
   PubMed Web of Science ®Google Scholar
• •Review of the clinical and vascular actions of statins.
   Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• ••Standard guidelines for management ofcardiovascular risk.
   Google Scholar
• WARNICK GR, MYERS GL, COOPER GR, RIFAI N: Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. Clin.Chem. (2002) 48:11–17.
   PubMed Web of Science ®Google Scholar
• WIERZBICKI AS, MIKHAILIDIS DP: Beyond LDL-C-the importance of raising HDL-C. Curl: Med. Res. Opin. (2002) 18:36–44.
   PubMed Web of Science ®Google Scholar
• WIERZBICKI AS, MIKHAILIDIS DP, WRAY R et al.: Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr. Med. Res. Opin. (2002) 19:155–168.
   Web of Science ®Google Scholar
• •Mechanistic and risk-benefit analysis of statin-fibrate combination therapy.
   Google Scholar
• HEINONEN OP, HUTTUNEN JK, MANNINEN V et al.: The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. I Intern. Med. (1994) 235:41–49.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl. I Med. (1999) 341:410–418.
   PubMed Web of Science ®Google Scholar
• ••Landmark trial of triglyceride reductionand HDL-C raising in a population with low LDL-C.
   Google Scholar
• HAIM M, BENDERLY M, BRUNNER D et al.: Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation (1999) 100:475–482.
   PubMed Web of Science ®Google Scholar
• The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl. J. Med. (1997) 336:153–162.
   PubMedGoogle Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7–22.
   PubMed Web of Science ®Google Scholar
• ••Landmark trial of benefits of reducing LDL-C by 1 mmol (25%) in all patients.
   Google Scholar
• FOX KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362:782–788.
   PubMed Web of Science ®Google Scholar
• ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al: Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. I Hum. Hypertens. (2004) (In Press).
   Google Scholar
• BAYS HE, McGOVERN ME: Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prey. Cardiol (2003) 6:179–188.
   PubMedGoogle Scholar
• •Beneficial effects of niacin-statin combination on lipid sub-fractions.
   Google Scholar
• BAYS HE, DUJOVNE CA, McGOVERN ME et al: Comparison of once-daily, niacin extended-release/ lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am. J. Cardiol (2003) 91:667–672.
   PubMed Web of Science ®Google Scholar
• CANNER PL, BERGE KG, WENGER NK et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol (1986) 8:1245–1255.
   PubMed Web of Science ®Google Scholar
• STEWART WJ, HOOGWERF BJ: Lipid-lowering therapy after coronary artery bypass surgery: the Post-CABG trial. Cleve. Clin. J. Med. (1997) 64:347–351.
   PubMed Web of Science ®Google Scholar
• McTAGGART F, BUCKETT L, DAVIDSON R et al.: Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. (2001) 87:28B–32B.
   Google Scholar
• OLSSON AG, PEARS J, McKELLAR J, MIZAN J, RAZA A: Effect of rosuvastatin on low-density lipoprotein cholesterol in 1414 patients with hypercholesterolemia. Am. J. Cardiol. (2001) 88:504–508.
   PubMed Web of Science ®Google Scholar
• CHONG PH, YIM BT: Rosuvastatin for the treatment of patients with hypercholesterolemia. Ann. Pharmacother. (2002) 36:93–101.
   PubMed Web of Science ®Google Scholar
• WOLFE SM: Dangers of rosuvastatin identified before and after FDA approval. Lancet (2004) 363:2189–2190.
   PubMed Web of Science ®Google Scholar
• VIDT DG, CRESSMAN MD, HARRIS S, PEARS JS, HUTCHINSON HG: Rosuvastatin-induced arrest in progression of renal disease. Cardiology (2004) 102:52–60.
   PubMed Web of Science ®Google Scholar
• KAJINAMI K, MABUCHI H, SAITO Y: NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin. Investig. Drugs (2000) 9:2653–2661.
   PubMed Web of Science ®Google Scholar
• NESS GC, ZHAO Z, KELLER RK: Effectof squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 a hydroxylase. Arch. Biochem.Biophys. (1994) 311:277–285.
   PubMed Web of Science ®Google Scholar
• HIYOSHI H, YANAGIMACHI M, ITO M et al.: Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur. j Pharmacol. (2001) 431:345–352.
   PubMed Web of Science ®Google Scholar
• WIERZBICKI AS: Editorial: Statins: myalgia and myositis. BE Cardiol. (2002) 9:193–194.
   Google Scholar
• SHARMA A, SLUGG PH, HAMMETT JL, JUSKO WJ: Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. Clin. Pharmacol. (1998) 38:1116–1121.
   Google Scholar
• BERGSTROM JD, KURTZ MM, REW DJ et al.: Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sri. USA (1993) 90:80–84.
   PubMed Web of Science ®Google Scholar
• AMIN D, RUTLEDGE RZ, NEEDLE SN et al.: RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. Pharmacol. Exp. Ther. (1997) 281:746–752.
   PubMed Web of Science ®Google Scholar
• UGAWA T, KAKUTA H, MORITANI H et al.: YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol. (2000) 131:63–70.
   PubMed Web of Science ®Google Scholar
• WIERZBICKI AS: Imidazole derivatives as cholesterol-lowering agents. Int. J. Cardiol. (2003) 90:145–146.
   Web of Science ®Google Scholar
• TAGHIBIGLOU C, VAN IDERSTINE SC, KULINSKI A, RUDY D, ADELI K: Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor. Biochem. Pharmacol. (2002) 63:349–360.
   PubMed Web of Science ®Google Scholar
• CHANG TY, CHANG CC, LIN S, YU C, LI BL, MIYAZAKI A: Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and -2. Curr. Opin. Lipidol. (2001) 12:289–296.
   PubMed Web of Science ®Google Scholar
• •Review of the actions of ACAT in cholesterol metabolism.
   Google Scholar
• BURNETT JR, WILCOX LJ, TELFORD DE et al.: Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J. Lipid Res. (1999) 40:1317–1327.
   PubMed Web of Science ®Google Scholar
• DELSING DJ, OFFERMAN EH, VAN DUYVENVOORDE W et al.: Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation (2001) 103:1778–1786.
   Google Scholar
• BOCAN TM, MUELLER SB, BROWN EQ et al.: HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit. Atherosclerosis (1998) 139:21–30.
   PubMed Web of Science ®Google Scholar
• INSULL W Jr, KOREN M, DAVIGNON J et al.:Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 157:137–144.
   PubMed Web of Science ®Google Scholar
• TARDIF JC, GREGOIRE J, LESPERANCE J et al.: Design features of the avasimibe and progression of coronary lesions assessed by intravascular ultrasound (A-PLUS) clinical trial. Am. Heart J. (2002) 144:589–596.
   PubMed Web of Science ®Google Scholar
• BURNETT JR, HUFF MW: Avasimibe Pfizer. Curr. Opin. Investig. Drugs (2002) 3:1328–1333.
   PubMedGoogle Scholar
• SAHI J, MILAD MA, ZHENG X et al.: Avasimibe induces CYP3A4 and MDR1 gene expression through activation of the pregnane X receptor. J. Pharmacol. Exp. Ther. (2003) 306(3):1027–1034.
   PubMed Web of Science ®Google Scholar
• WIERZBICKI AS: Atorvastatin. Expert Opin. Pharmacother. (2001) 2:819–830.
   PubMedGoogle Scholar
• JAMIL H, CHU CH, DICKSON JK Jr et al.: Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells. I Lipid Res. (1998) 39:1448–1454.
   Google Scholar
• WETTERAU JR, GREGG RE, HARRITY TW et al.: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science (1998) 282:751–754.
   PubMed Web of Science ®Google Scholar
• SHIOMI M, ITO T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur. Pharmacol. (2001) 431:127–131.
   PubMed Web of Science ®Google Scholar
• JIN FY, KAMANNA VS, KASHYAP ML: Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1051–1059.
   PubMed Web of Science ®Google Scholar
• GYLLING H, MIETTINEN TA: Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism (1999) 48:575–580.
   PubMed Web of Science ®Google Scholar
• WASAN KM, ZAMFIR C, PRITCHARD PH, PEDERSON RA: Influence of Phytostanol Phosphoryl Ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats../. Pharm. Sri. (2003) 92:281–288.
   PubMed Web of Science ®Google Scholar
• LEITERSDORF E: Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. Int. I Clin. Pract. (2002) 56:116–119.
   PubMed Web of Science ®Google Scholar
• ALTMANN SW, DAVIS HR Jr et al.: Niemann-Pick Cl Like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 303:1201–1204.
   Google Scholar
• •Identification of a novel protein involved In intestinal cholesterol uptake.
   Google Scholar
• SMART EJ, DE ROSE RA, FARBER SA: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl. Acad. Sci. USA (2004) 101:3450–3455.
   PubMed Web of Science ®Google Scholar
• BALLANTYNE CM, HOURI J, NOTARBARTOLO A et al.: Effect of ezetimibe coadministered with atorvastatin 1415 Expert Opin. Investig. Drugs (2004) 13(11) in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation (2003) 107:2409–2415.
   Google Scholar
• KOSOGLOU T, STATKEVICH P, FRUCHART JC et al: Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr. Med. Res. Opin. (2004) 20:1197–207.
   PubMed Web of Science ®Google Scholar
• GAGNE C, GAUDET D, BRUCKERT E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 105:2469–2475.
   PubMed Web of Science ®Google Scholar
• BAYS HE, MOORE PB, DREHOBL MA et al.: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two Phase II studies. Clin.Ther. (2001) 23:1209–1230.
   PubMed Web of Science ®Google Scholar
• MAURO VF, TIJCKERMAN CE: Ezetimibe for management of hypercholesterolemia. Ann. Pharmacother. (2003) 37:839–848.
   PubMed Web of Science ®Google Scholar
• WIERZBICKI AS, DOHERTY E, LUMB PJ, CHIK G, CROOK MA: Efficacy of ezetimibe in statin-resistant and statin-intolerant patients with familial hyperlipidaemias. Curr. Med. Res. Opin. (2004) (in press).
   Google Scholar
• BALLANTYNE CM, BLAZING MA, KING TR, BRADY WE, PALMISANO J: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol (2004) 93:1487–1494.
   PubMed Web of Science ®Google Scholar
• BUCHWALD H, VARCO RL, MATTS JP et al: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl. Med. (1990) 323:946–955.
   Google Scholar
• •Relationship of PPAR action to lipid metabolism in diabetes.
   Google Scholar
• Pamaqueside. CP 148623. Drugs RD (2002) 3:175–176.
   PubMedGoogle Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA (1984) 251:351–364.
   Google Scholar
• INSULL W Jr, TOTH P, MULLICAN W et al.: Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc. (2001) 76:971–982.
   PubMed Web of Science ®Google Scholar
• HUNNINGHAKE D, INSULL W Jr, TOTH P, DAVIDSON D, DONOVAN JM, BURKE SK: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis (2001) 158:407–416.
   PubMed Web of Science ®Google Scholar
• KNAPP HH, SCHROTT H, MAP et al: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. (2001) 110:352–360.
   PubMed Web of Science ®Google Scholar
• EDWARDS PA, KAST HR, ANISFELD AM: BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. (2002) 43:2–12.
   PubMed Web of Science ®Google Scholar
• •Review of the actions of the liver and famesoid X receptors in lipid metabolism.
   Google Scholar
• HIGAKI J, HARA S, TAKASU N et al: Inhibition of ileal Na*/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1304–1311.
   PubMed Web of Science ®Google Scholar
• ROBINS SJ, COLLINS D, WITTES JT et al: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA (2001) 285:1585–1591.
   PubMed Web of Science ®Google Scholar
• CORN WELL PD, DE SOUZA AT, ULRICH RG: Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mutat. Res. (2004) 549:131–145.
   PubMed Web of Science ®Google Scholar
• •Pleiotropic actions of PPAR-a agonists on gene expression.
   Google Scholar
• YIN W, TSUTSUMI K: Lipoprotein lipase activator NO-1886. Cardiovasc. Drug Rev (2003) 21:133–142.
   PubMedGoogle Scholar
• YIN W, YUAN Z, TSUTSUMI K et al: A lipoprotein lipase-promoting agent, NO-1886, improves glucose and lipid metabolism in high fat, high sucrose-fed New Zealand white rabbits. Int. I Exp. Diabetes Res. (2003) 4:27–34.
   Google Scholar
• FERRE P: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes (2004) 53\(Suppl. 1):543–550.
   Google Scholar
• GUPTA RA, WANG D, KATKURI S, WANG H, DEY SK, DUBOIS RN: Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-8 accelerates intestinal adenoma growth. Nat. Med. (2004) 10:245–247.
   PubMed Web of Science ®Google Scholar
• IDZIOR-WALUS B, SIERADZKI J, ROSTWOROWSKI W et al: Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur. j Clin. Invest. (2000) 30:871–878.
   PubMed Web of Science ®Google Scholar
• LOHRAY BB, LOHRAY VB, BAJJI AC et al: ()3 [4 [2 (Phenoxazin-10-34)ethoxy[pheny11-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. (2001) 44:2675–2678.
   PubMed Web of Science ®Google Scholar
• SHIBATA T, TAKEUCHI S, YOKOTA S, KAKIMOTO K, YONEMORI F, WAKITANI K: Effects of peroxisome proliferator-activated receptor-a and -y agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. BE J. Pharmacol (2000) 130:495–504.
   PubMed Web of Science ®Google Scholar
• ETGEN GJ, OLDHAM BA, JOHNSON WT et al.: A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-a/y agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes (2002) 51:1083–1087.
   PubMed Web of Science ®Google Scholar
• YAJIMA K, HIROSE H, FUJITA H et al:Combination therapy with PPARy and PPARa agonists increases glucose-stimulated insulin secretion in db/db mice. Am. I Physiol Endocrinol Metab. (2003) 284:E966–E971.
   PubMed Web of Science ®Google Scholar
• CALKIN AC, THOMAS MC, COOPER ME: MK-767. Kyorin/Banyu/ Merck. Curr. Opin. Investig. Drugs (2003) 4:444–448.
   PubMedGoogle Scholar
• ERICSSON H, HAMREN B, BERGSTRAND S et al: Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator activated receptor {Wi{y} agonist, after a single oral and intravenous dose in humans. Drug Metab. Dispos. (2004) 32:923–929.
   PubMed Web of Science ®Google Scholar
• SAAD ME GRECO S, OSEI K et al: Ragaglitazar improves glycemic control and lipid profile in Type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care (2004) 27:1324–1329.
   PubMed Web of Science ®Google Scholar
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italian° per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet (1999) 354:447–455.
   Google Scholar
• MARCHIOLI R, BARZI F, BOMBA E et al.: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italian° per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation (2002) 105:1897–903.
   PubMed Web of Science ®Google Scholar
• MORTON RE: Cholesteryl ester transferprotein and its plasma regulator: lipid transfer inhibitor protein. Curr. Opin. Lipidel (1999) 10:321–327.
   PubMed Web of Science ®Google Scholar
• •Review of the role of CETP in lipid metabolism.
   Google Scholar
• OKAMOTO H, YONEMORI F, WAKITANI K, MINOWA T, MAEDA K, SHINKAI H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406:203–207.
   PubMed Web of Science ®Google Scholar
• HUANG Z, INAZU A, NOHARA A, HIGASHIKATA T, MABUCHI H: Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Li. (2002) 103:587–594.
   Google Scholar
• DE GROOTH GJ, KUIVENHOVEN JA, STALENHOEF AF et al: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized Phase II dose-response study. Circulation (2002) 105:2159–2165.
   PubMed Web of Science ®Google Scholar
• CLARK RW, SUTFIN TA, RUGGERI RB et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biel (2004) 24:490–497.
   PubMed Web of Science ®Google Scholar
• BROUSSEAU ME, SCHAEFER EJ, WOLFE ML et al: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl. J. Med. (2004) 350:1505–1515.
   PubMed Web of Science ®Google Scholar
• •Efficacy of CETP inhibition on HDL-C levels in man.
   Google Scholar
• DAVIDSON MH, MAKI K, UMPOROWICZ D, WHEELER A, RITTERSHAUS C, RYAN U: The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis (2003) 169:113–120.
   PubMed Web of Science ®Google Scholar
• SRIVASTAVA RA, SRIVASTAVA N: High density lipoprotein, apolipoprotein A-I, and coronary artery disease. MolCell Biochem. (2000) 209:131–144.
   Web of Science ®Google Scholar
• NEWTON RS, KRAUSE BR: HDL therapy for the acute treatment of atherosclerosis. Atheraccler. Suppl. (2002) 3:31–38.
   PubMed Web of Science ®Google Scholar
• CHIESA G, SIRTORI CR: Apolipoprotein A-I Milano: current perspectives. Curr. Opin. Lipidel (2003) 14:159–163.
   PubMed Web of Science ®Google Scholar
• KLON AE, JONES MK, SEGREST JP, HARVEY SC: Molecular belt models for the apolipoprotein A-I Paris and Milano mutations. Biephys..1. (2000) 79: 1679-1685.
   Google Scholar
• CHIESA G, MONTEGGIA E, MARCHESI M et al: Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ. Res. (2002) 90:974–980.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TSUNODA T, ITJZCU EM et al: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 290:2292–300.
   PubMed Web of Science ®Google Scholar
• ••Efficacy of infusion of HDL mimetic oncoronary atherosclerosis in man.
   Google Scholar
• MERTENS A, HOLVOET P: Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB (2001) 15:2073–2084.
   PubMed Web of Science ®Google Scholar
• PACKARD CJ, O'REILLY DS, CASLAKE MJ et al: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl. I Med. (2000) 343:1148–1155.
   PubMed Web of Science ®Google Scholar
• BLACKIE JA, BLOOMER JC, BROWN MJ et al: The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A(2). Bieerg. Med. Chem. Lett. (2003) 13:1067–1070.
   PubMed Web of Science ®Google Scholar
• SHLIPAK MG, SIMON JA, VITTINGHOFF E et al.: Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA (2000) 283:1845–1852.
   PubMed Web of Science ®Google Scholar
• BERGLUND L, CARLSTROM K, STEGE R et al: Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J. Clin. Endocrine] Metab. (1996) 81:2633–2637.
   PubMed Web of Science ®Google Scholar
• SHARP RJ, PERUGINI MA, MARCOVINA SM, McCORMICK SP: A synthetic peptide that inhibits lipoprotein(a) assembly. Arterioscler. Thromb. Vasc. Biel (2003) 23:502–507.
   PubMed Web of Science ®Google Scholar
• SUNDELL CL, SOMERS PK, MENG CQ et al: AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. Pharmacol Exp. Ther. (2003) 305:1116–1123.
   PubMed Web of Science ®Google Scholar
• •Review of the actions of an anti-inflammatory modulator derived from the lipid-lowering drug probucol.
   Google Scholar
• TARDIF JC: Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am. J. Cardiel (2003) 91:41A–49A.
   Google Scholar
• TARDIF JC, GREGOIRE J, SCHWARTZ L et al: Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation (2003) 107:552–558.
   PubMed Web of Science ®Google Scholar
• WALD NJ, LAW MR: A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. (2003) 326:1419.
   PubMed Web of Science ®Google Scholar
• •Theoretical benefits of optimal pharmacological management to cardiovascular risk.
   Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch. Intern. Med. (1992) 152:1399–1410.
   Google Scholar
• WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet (1984) 2:600–604.
   PubMedGoogle Scholar
• HUTTUNEN JK, HEINONEN OP, MANNINEN V et al.: The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J. Intern. Med (1994) 235:31–39.
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl. J. Med (1996) 335:1001–1009.
   Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al: Prevention of coronary heart disease (2004) 13(11) with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl. Med (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• ATHYROS VG, PAPAGEORGIOU AA, MERCOURIS BR et al.: Treatment with atorvastatin to the National Cholesterol Educational Program Goals versus Usual Care in Secondary Coronary Heart Disease Prevention. The Greek Atorvastatin and Coronary-Heart-disease Evaluation (GREACE) Study. Curc Med. Res. Opin. (2002) 18:220–228.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, BLAUW GJ, MURPHY MB et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360:1623–1630.
   PubMed Web of Science ®Google Scholar
• SEVER PS, DAHLOF B, POULTER NR et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361:1149–1158.
   PubMed Web of Science ®Google Scholar
• COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364:685-696. Affiliation
   Google Scholar